AstraZeneca Results Presentation Deck
FY 2020: diversified and double-digit growth
Oncology, US, Emerging markets drove performance
Total revenue
Oncology
New CVRM
Respiratory &
Immunology
Other medicines
Q4 2020
$m
7,410
3,270
1,252
1,534
1,354
Growth across
therapy areas
growth
%
Total revenue at actual exchange rates; changes at CER.
9
10
23
7
(2)
2
ratio
%
100
44
17
21
18
FY 2020
$m
26,617
11,455
4,702
5,375
5,085
growth
%
10
24
(0)
(2)
ratio
%
100
43
18
20
19
Total revenue
US
EMs¹
- EMS ex China
- China
Europe
Established
rest of world
Q4 2020
$m
7,410
2,388
2,244
882
1,362
1,831
947
Growth across
geographies
growth
%
10
15
8
7
9
12
(1)
ratio
%
100
32
30
12
18
25
13
Total revenue at actual exchange rates; changes at CER. 1. Emerging markets.
FY 2020
$m
26,617
8,833
8,711
3,336
5,375
5,540
3,533
growth
%
10
13
10
11
9
LO
ratio
%
100
33
33
13
20
21
13
BView entire presentation